J
Jennifer N. Durham
Researcher at Johns Hopkins University
Publications - 39
Citations - 5870
Jennifer N. Durham is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Nivolumab & GVAX. The author has an hindex of 12, co-authored 29 publications receiving 3797 citations. Previous affiliations of Jennifer N. Durham include Johns Hopkins University School of Medicine & Swim Across America.
Papers
More filters
Journal ArticleDOI
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le,Dung T. Le,Jennifer N. Durham,Jennifer N. Durham,Kellie N. Smith,Hao Wang,Bjarne Bartlett,Bjarne Bartlett,Laveet K. Aulakh,Laveet K. Aulakh,Steve Lu,Steve Lu,Holly Kemberling,Cara Wilt,Brandon Luber,Fay Wong,Fay Wong,Nilofer S. Azad,Agnieszka A. Rucki,Daniel A. Laheru,Ross C. Donehower,Atif Zaheer,George A. Fisher,Todd S. Crocenzi,James J. Lee,Tim F. Greten,Austin G. Duffy,Kristen K. Ciombor,Aleksandra Eyring,Bao H. Lam,Andrew K. Joe,S. Peter Kang,Matthias Holdhoff,Ludmila Danilova,Leslie Cope,Christian F. Meyer,Shibin Zhou,Shibin Zhou,Richard M. Goldberg,Deborah K. Armstrong,Katherine M. Bever,Amanda N. Fader,Janis M. Taube,Franck Housseau,David Spetzler,Nianqing Xiao,Drew M. Pardoll,Nickolas Papadopoulos,Nickolas Papadopoulos,Kenneth W. Kinzler,Kenneth W. Kinzler,James R. Eshleman,Bert Vogelstein,Bert Vogelstein,Robert A. Anders,Robert A. Anders,Luis A. Diaz,Luis A. Diaz +57 more
TL;DR: Evaluating the efficacy of PD-1 blockade in patients with advanced mismatch repair–deficient cancers across 12 different tumor types showed that colorectal cancers with mismatch repair deficiency were sensitive to immune checkpoint blockade with antibodies to programmed death receptor–1 (PD-1).
Journal ArticleDOI
Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response
Rajarsi Mandal,Rajarsi Mandal,Robert M. Samstein,Ken-Wing Lee,Jonathan J. Havel,Hao Wang,Chirag Krishna,Erich Y. Sabio,Vladimir Makarov,Fengshen Kuo,Pedro Blecua,Apoorva T. Ramaswamy,Jennifer N. Durham,Jennifer N. Durham,Bjarne Bartlett,Xiaoxiao Ma,Raghvendra M. Srivastava,Sumit Middha,Ahmet Zehir,Jaclyn F. Hechtman,Luc G. T. Morris,Nils Weinhold,Nadeem Riaz,Dung T. Le,Dung T. Le,Luis A. Diaz,Timothy A. Chan +26 more
TL;DR: Experimental and clinical evidence is presented showing that the degree of microsatellite instability (MSI) and resultant mutational load, in part, underlies the variable response to PD-1 blockade immunotherapy in MMR-d human and mouse tumors.
Journal ArticleDOI
T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma
Alexander Hopkins,Mark Yarchoan,Jennifer N. Durham,Erik Yusko,Julie A. Rytlewski,Harlan Robins,Daniel A. Laheru,Dung T. Le,Eric R. Lutz,Elizabeth M. Jaffee +9 more
TL;DR: It is shown that these therapies have measurably different effects on the peripheral repertoire, consistent with their mechanisms of action, and the potential for TCR repertoire profiling to serve as a biomarker of clinical response in pancreatic cancer patients receiving immunotherapy is demonstrated.
Journal ArticleDOI
Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity
Won Jin Ho,Qingfeng Zhu,Jennifer N. Durham,Aleksandra Popovic,Stephanie Xavier,James M. Leatherman,Aditya Mohan,Guanglan Mo,Shu Zhang,Nicole Gross,Soren Charmsaz,Dongxia Lin,Derek Quong,Brad Wilt,Ihab R. Kamel,Matthew J. Weiss,Benjamin Philosophe,Richard A. Burkhart,William R. Burns,Chris Shubert,Aslam Ejaz,Jin He,Atul Deshpande,Ludmila Danilova,Genevieve Stein-O’Brien,Elizabeth A. Sugar,Daniel A. Laheru,Robert A. Anders,Elana J. Fertig,Elizabeth M. Jaffee,Mark Yarchoan +30 more
TL;DR: In-depth biospecimen profiling demonstrated an enrichment in T effector cells, as well as tertiary lymphoid structures, CD138+ plasma cells, and a distinct spatial arrangement of B cells in responders as compared to non-responders, indicating an orchestrated B-cell contribution to antitumor immunity in HCC.
Journal ArticleDOI
Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade.
Andrew Georgiadis,Jennifer N. Durham,Laurel Keefer,Bjarne Bartlett,Bjarne Bartlett,Magdalena Zielonka,Derek Murphy,James R. White,Steve Lu,Ellen L. Verner,Finey Ruan,David R. Riley,Robert A. Anders,Erika Gedvilaite,Samuel V. Angiuoli,Siân Jones,Victor E. Velculescu,Dung T. Le,Luis A. Diaz,Mark Sausen +19 more
TL;DR: These analyses demonstrate the feasibility of noninvasive pan-cancer screening and monitoring of patients who exhibit MSI or TMB-High and have a high likelihood of responding to immune checkpoint blockade.